Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study

Table 2 Univariate and multivariate analysis of progression free survival (PFS) in EGFR gene negative NSCLC patients

	Univariate analysis		Multivariate analysis
	P value	95% CI	P value	HR (95% CI)
Sex	0.968	0.456–2.269	0.384	0.086–2.574
Smoking	0.920	0.502–2.145	0.383	0.108–2.351
ECOG PS	0.134	0.757–8.083	0.124	0.748–11.014
Histological	0.302	0.436–1.294	0.080	0.299–1.072
Liver metastases	0.016	1.200–5.966	0.061	0.961–5.597
Brain metastases	0.262	0.640–5.156	0.835	0.239–3.181
Anlotinib treatment modes	0.014	0.270–0.862	0.004	0.182–0.731
Lines of Anlotinib treatment	0.740	0.873–1.944	0.901	0.427–2.628

ISSN: 1471-2466